JOHN KIRKWOOD to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
2.604
-
Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends Cancer. 2020 09; 6(9):797-810.
Score: 0.157
-
E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-a2b in Advanced Melanoma. Clin Cancer Res. 2019 01 15; 25(2):524-532.
Score: 0.141
-
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017 11 09; 377(19):1813-1823.
Score: 0.130
-
Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-a2b in patients with metastatic melanoma. Melanoma Res. 2017 08; 27(4):342-350.
Score: 0.129
-
BRAF Inhibitors and IFNa: Plus, Minus, or Indeterminate? J Natl Cancer Inst. 2016 Jul; 108(7).
Score: 0.116
-
CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux. Clin Cancer Res. 2015 Dec 15; 21(24):5412-4.
Score: 0.115
-
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014 Nov 05; 312(17):1744-53.
Score: 0.106
-
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013 Jan 20; 31(3):373-9.
Score: 0.093
-
Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-a or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother. 2012 Nov-Dec; 35(9):702-10.
Score: 0.093
-
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol. 2012 Jan 20; 30(3):322-8.
Score: 0.087
-
A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma. Cancer. 2011 Oct 15; 117(20):4732-9.
Score: 0.083
-
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer. 2009 Feb 15; 115(4):859-68.
Score: 0.072
-
Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res. 2007 Jun; 17(3):193-200.
Score: 0.064
-
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004 Aug; 40(12):1825-36.
Score: 0.052
-
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C?melanoma is removed by surgery. Future Oncol. 2024 May; 20(15):959-968.
Score: 0.051
-
Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study. Immunotherapy. 2024 Jan; 16(1):29-42.
Score: 0.050
-
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2023 Dec 14; 389(24):2256-2266.
Score: 0.049
-
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023 Nov; 29(11):2835-2843.
Score: 0.049
-
Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. Cancer. 2003 Jan 01; 97(1):121-7.
Score: 0.047
-
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023 01 10; 41(2):186-197.
Score: 0.046
-
Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling. Pigment Cell Melanoma Res. 2022 01; 35(1):66-77.
Score: 0.043
-
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020 09 17; 383(12):1139-1148.
Score: 0.040
-
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer. 2020 06; 8(1).
Score: 0.039
-
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020 03; 21(3):358-372.
Score: 0.038
-
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2019 12 10; 37(35):3350-3358.
Score: 0.037
-
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 05; 20(5):701-710.
Score: 0.036
-
Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gaq and Ga11 and kill uveal melanoma cells. Cancer Biol Ther. 2019; 20(5):700-710.
Score: 0.035
-
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer. 2018 11 15; 124(22):4332-4341.
Score: 0.035
-
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
Score: 0.033
-
The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib. Cancer Biol Ther. 2018 02 01; 19(2):132-137.
Score: 0.033
-
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. J Clin Oncol. 2018 02 01; 36(4):391-398.
Score: 0.033
-
High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med. 2017 Nov; 6(11):2576-2585.
Score: 0.033
-
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res. 2016 Jan 15; 22(2):374-82.
Score: 0.028
-
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18.
Score: 0.028
-
Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol. 2014 Nov 20; 32(33):3771-8.
Score: 0.027
-
Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res. 2014 Jun; 24(3):207-18.
Score: 0.026
-
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res. 2014 Jun 15; 20(12):3328-37.
Score: 0.026
-
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res. 2012 Feb 15; 18(4):1129-37.
Score: 0.022
-
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer. 2010 Mar 15; 116(6):1526-34.
Score: 0.019
-
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009 Jun 10; 27(17):2823-30.
Score: 0.018
-
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008 Dec 10; 26(35):5748-54.
Score: 0.018
-
A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma. Cancer. 2008 Oct 01; 113(7):1632-40.
Score: 0.017
-
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol. 2008 May 10; 26(14):2292-8.
Score: 0.017
-
Focus on FOCIS: interleukin 2 treatment associated autoimmunity. Clin Immunol. 2008 May; 127(2):123-9.
Score: 0.017
-
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008 May 01; 26(13):2178-85.
Score: 0.017
-
Management of metastatic melanoma. Semin Oncol. 2007 Dec; 34(6):532-45.
Score: 0.016
-
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol. 2007 Sep 01; 25(25):3802-7.
Score: 0.016
-
Systemic Therapy for Melanoma: ASCO Guideline Update. J Clin Oncol. 2023 10 20; 41(30):4794-4820.
Score: 0.012
-
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. J Immunother Cancer. 2023 06; 11(6).
Score: 0.012
-
Medical management of melanoma. Surg Clin North Am. 2003 Apr; 83(2):283-322, viii.
Score: 0.012
-
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. Clin Cancer Res. 2023 02 01; 29(3):521-531.
Score: 0.012
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2022 11; 23(11):1378-1388.
Score: 0.012
-
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022 04 30; 399(10336):1718-1729.
Score: 0.011
-
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002 Jan 01; 20(1):125-33.
Score: 0.011
-
Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol. 2020 11 20; 38(33):3947-3970.
Score: 0.010
-
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol. 2018 12 10; 36(35):3441-3449.
Score: 0.009
-
Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. J Immunother Cancer. 2018 10 19; 6(1):108.
Score: 0.009
-
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget. 2017 Mar 07; 8(10):16367-16386.
Score: 0.008
-
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013 Feb 10; 31(5):616-22.
Score: 0.006
-
Chemotherapy for metastatic melanoma: time for a change? Cancer. 2007 Feb 01; 109(3):455-64.
Score: 0.004
-
Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res. 2003 Dec; 13(6):619-26.
Score: 0.003